Get started
Author

Keith A. Riccardi

Observed names: K Riccardi, K. A. Riccardi, K. Riccardi, K.A. Riccardi, Keith Riccardi, Riccardi Keith, Riccardi, Keith A.
OpenAlex ID: A5039748175
BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents
2000 · Brett S. Robinson, Keith A. Riccardi, et al. · Antimicrobial Agents and Chemotherapy · 198
Systematic Evaluation of Bioorthogonal Reactions in Live Cells with Clickable HaloTag Ligands: Implications for Intracellular Imaging
2015 · Heather E. Murrey, Joshua C. Judkins, et al. · Journal of the American Chemical Society · 189
Plasma Protein Binding of Challenging Compounds
2015 · Keith Riccardi, Shannon Cawley, et al. · Journal of Pharmaceutical Sciences · 119
A “middle-out” approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling
2014 · Rui Li, Hugh A. Barton, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 76
Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5)
2015 · Kim Huard, Janice Brown, et al. · Scientific Reports · 69
PDF
Inhibitors of HIV-1 attachment. Part 7: Indole-7-carboxamides as potent and orally bioavailable antiviral agents
2012 · Kap-Sun Yeung, Zhilei Qiu, et al. · Bioorganic & Medicinal Chemistry Letters · 53
Novel Method to Predict In Vivo Liver-to-Plasma Kpuu for OATP Substrates Using Suspension Hepatocytes
2017 · Keith Riccardi, Jian Lin, et al. · Drug Metabolism and Disposition · 51
A Novel Unified Approach to Predict Human Hepatic Clearance for Both Enzyme- and Transporter-Medated Mechanisms Using Suspended Human Hepatocytes
2019 · Keith A. Riccardi, David A. Tess, et al. · Drug Metabolism and Disposition · 46
PDF
Comparison of Species and Cell-Type Differences in Fraction Unbound of Liver Tissues, Hepatocytes, and Cell Lines
2018 · Keith Riccardi, Sangwoo Ryu, et al. · Drug Metabolism and Disposition · 44
PDF
Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor
1996 · P F Lin, H Samanta, et al. · Antimicrobial Agents and Chemotherapy · 44
Inhibitors of HIV-1 attachment. Part 8: The effect of C7-heteroaryl substitution on the potency, and in vitro and in vivo profiles of indole-based inhibitors
2012 · Kap-Sun Yeung, Zhilei Qiu, et al. · Bioorganic & Medicinal Chemistry Letters · 40
Mechanistic insights on clearance and inhibition discordance between liver microsomes and hepatocytes when clearance in liver microsomes is higher than in hepatocytes
2020 · Christopher Keefer, George Chang, et al. · European Journal of Pharmaceutical Sciences · 39
Inhibitors of HIV-1 attachment. Part 9: An assessment of oral prodrug approaches to improve the plasma exposure of a tetrazole-containing derivative
2012 · Kap-Sun Yeung, Zhilei Qiu, et al. · Bioorganic & Medicinal Chemistry Letters · 39
Evaluation of Fraction Unbound Across 7 Tissues of 5 Species
2019 · Sangwoo Ryu, David Tess, et al. · Journal of Pharmaceutical Sciences · 38
BMP-6 exerts its osteoinductive effect through activation of IGF-I and EGF pathways
2007 · W. A. Grasser, I. Orlic, et al. · International Orthopaedics · 35
PDF
Inhibitors of HIV-1 attachment. Part 10. The discovery and structure–activity relationships of 4-azaindole cores
2012 · Tao Wang, Zhong Yang, et al. · Bioorganic & Medicinal Chemistry Letters · 33
Evolving approaches on measurements and applications of intracellular free drug concentration and Kpuu in drug discovery
2021 · Li Di, Keith Riccardi, et al. · Expert Opinion on Drug Metabolism & Toxicology · 32
Determination of Unbound Partition Coefficient and in Vitro–in Vivo Extrapolation for SLC13A Transporter–Mediated Uptake
2016 · Keith Riccardi, Zhenhong Li, et al. · Drug Metabolism and Disposition · 32
Structural attributes influencing unbound tissue distribution
2019 · Christine C. Orozco, Karen Atkinson, et al. · European Journal of Medicinal Chemistry · 31
Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonists
2009 · Mary T. Didiuk, David A. Griffith, et al. · Bioorganic & Medicinal Chemistry Letters · 25
Quantitative systems toxicology (QST) reproduces species differences in PF‐04895162 liver safety due to combined mitochondrial and bile acid toxicity
2019 · Grant Generaux, Vinal V. Lakhani, et al. · Pharmacology Research & Perspectives · 22
PDF
Applying Two Orthogonal Methods to Assess Accuracy of Plasma Protein Binding Measurements for Highly Bound Compounds
2019 · Sangwoo Ryu, Keith Riccardi, et al. · Journal of Pharmaceutical Sciences · 21
A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 1: Translating Systemic Plasma Concentration to Liver Exposure in Healthy Subjects
2018 · Rui Li, Mark Niosi, et al. · Drug Metabolism and Disposition · 21
PDF
Structural Analysis of the Native and Drug Resistant HIV-1 Proteinases Complexed With an Aminodiol Inhibitor
1996 · Alexander Wlodawer, Jukka Kervinen, et al. · Protein and Peptide Letters · 19
Clinical HIV-1 isolates remain sensitive to stavudine following prolonged therapy.
1998 · C A Deminie, C M Bechtold, et al. · PubMed · 18
Works count: 48
Citation count: 1,444
H-index: 21
I10-index: 31
Year
Topic
Type